



2021 American Society of Hematology (ASH) Annual Conference

TAKEDA ONCOLOGY
SPONSORED ABSTRACTS

Learn more at [takedaoncology.com](https://www.takedaoncology.com)

    @TakedaOncology

All trademarks are the property of their respective owners.
©2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.



ONCOLOGY

ABSTRACT #	TITLE	SESSION
------------	-------	---------

HODGKIN LYMPHOMA

[ABSTRACT
1397](#)

Use of Positron Emission Tomography in Patients With Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-center, Retrospective B-HOLISTIC Study

POSTER PRESENTATION

Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I

December 11, 2021
5:30-7:30 PM ET

Location: Hall B5



CHRONIC MYELOID LEUKEMIA

[ABSTRACT
307](#)

Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR-ABL1 level and Baseline Mutation Status in the OPTIC Trial

ORAL PRESENTATION

Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies

December 11, 2021
4:00-5:30 PM ET

Location: B304-B305



[ABSTRACT
2550](#)

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) From the PACE and OPTIC Trials

POSTER PRESENTATION

Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

December 12, 2021
6:00-8:00 PM ET

Location: Hall B5



MULTIPLE MYELOMA

[ABSTRACT
898](#)

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

ORAL PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma

December 13, 2021
6:15-7:45 PM ET

Location: A411-A412



[ABSTRACT
1666](#)

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (dex; IDd) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) with 1-3 Prior Therapies: Results of the Second Interim Analysis (IA2) of a Phase 2 Study

POSTER PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

December 11, 2021
5:30-7:30 PM ET

Location: Hall B5



[ABSTRACT
1656](#)

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

POSTER PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

December 11, 2021
5:30-7:30 PM ET

Location: Hall B5

[ABSTRACT
1678](#)

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

POSTER PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

December 11, 2021
5:30-7:30 PM ET

Location: Hall B5

ABSTRACT #	TITLE	SESSION
------------	-------	---------

MULTIPLE MYELOMA (CONTINUED)

ABSTRACT
2733

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

POSTER PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

December 12, 2021
6:00-8:00 PM ET

Location: Hall B5



ABSTRACT
2701

The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice

POSTER PRESENTATION

Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological

December 12, 2021
6:00-8:00 PM ET

Location: Hall B5

ABSTRACT
2726

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

POSTER PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials

December 12, 2021
6:00-8:00 PM ET

Location: Hall B5

ABSTRACT
3045

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

POSTER PRESENTATION

Outcomes Research—Lymphoid Malignancies: Poster II

December 12, 2021
6:00-8:00 PM ET

Location: Hall B5

HIGHER-RISK MYELODYSPLASTIC SYNDROMES

ABSTRACT
242

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 Panther Trial (NCT03268954)

ORAL PRESENTATION

Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High Risk Myelodysplastic Syndrome

December 11, 2021
2:00-3:30 PM ET

Location: B207-B208



PIPELINE

ABSTRACT
2742

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination With Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

POSTER PRESENTATION

Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II

December 12, 2021
6:00-8:00 PM ET

Location: Hall B5



ABSTRACT
2488

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

POSTER PRESENTATION

Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II

December 12, 2021
6:00-8:00 PM ET

Location: Hall B5